Low response to high-dose intravenous immunoglobulin in the treatment of acquired factor VIII inhibitor

Authors


Dr Laurent Crenier Clinique d'Hématologie (Département de Médecine Interne), Hôpital Ulb-Erasme, 808 route de Lennik, B-1070 Brussels, Belgium.

Abstract

Prednisone is the classic first-line therapy to suppress an acquired factor VIII inhibitor and may achieve complete remission in about 30% of patients. More recently, promising results have been reported with high-dose intravenous immunoglobulin (IVIg). However, after an extensive review of the literature, we found only three complete remissions (12%) among the 26 assessable patients treated by IVIg. These data are in agreement with the low response to IVIg that we experienced in our series of patients. This study suggests that steroids should still be preferred to IVIg, an expansive therapy, to suppress an acquired factor VIII inhibitor.

Ancillary